More articles from Therapeutic Agents: Biological

Abstract B121: The benefits of bispecific mAb² antibodies targeting EGFR and HGF
Kin-Mei Leung

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B121; DOI: 10.1158/1535-7163.TARG-17-B121
Abstract B107: Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
Marc Hillairet de Boisferon, Caroline Mignard, Coralie Durix, Toshimitsu Uenaka, Katherine Rybinski, Xin Cheng, Keiji Furuuchi, Eart Albone

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B107; DOI: 10.1158/1535-7163.TARG-17-B107
Abstract B103: A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate in preclinical studies
Laura Serwer, Shweta Singh, Claus Krebber, Shouchun Liu, Niharika Chauhan, Robert Leanna, Hong Lu, Ilaria Badagnani, Tracy Henriques, Susan Morgan-Lappe, William Mylott, Sridhar Viswanathan, Jennifer Richardson, Michael Kavanaugh

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B103; DOI: 10.1158/1535-7163.TARG-17-B103
Abstract B109: ASN004, a novel 5T4-targeted Dolaflexin ADC, causes complete and durable tumor regression in a variety of tumor xenograft models
Roger A. Smith, David J. Zammit, Sanjeeva P. Reddy

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B109; DOI: 10.1158/1535-7163.TARG-17-B109
Abstract B114: Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo
Daniel Dransfield, Jillian M. Prendergast, David A. Eavarone, Rawan Nazer, Linah Al-Alem, Bo Rueda, Jenna Stein, Jeff Behrens

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B114; DOI: 10.1158/1535-7163.TARG-17-B114
Abstract B118: Potentiation of IL-2’s antitumor efficacy without compromised tolerability by a novel human antibody
Kirk Johnson, Ou Li, Xiaohe Liu, Lucia Beviglia

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B118; DOI: 10.1158/1535-7163.TARG-17-B118
Abstract LB-B23: Prodrug activation by designer enzyme targeted to CD123-expressing tumors
Bengt Mannervik, Birgitta I. Sjödin

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) LB-B23; DOI: 10.1158/1535-7163.TARG-17-LB-B23
Abstract B119: Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
Rebecca Mosher, Laura Poling, LiuLiang Qin, Natalya Bodyak, Donald Bergstrom

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B119; DOI: 10.1158/1535-7163.TARG-17-B119
Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
Shweta Singh, Laura Serwer, Niharika Chauhan, Amy DuPage, Michael Krimm, Ken Wong, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Fritz Buchanan, Matthew M. Ravn, Rob Leanna, Ilaria Badagnani, Tracy Henriques, Shouchun Liu, Claus Krebber, Sridhar Viswanathan, Jennifer Richardson, Susan Morgan-Lappe, Michael Kavanaugh

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B116; DOI: 10.1158/1535-7163.TARG-17-B116
Abstract B117: Phase II study of brentuximab vedotin and bevacizumab in GCT
Shilpa Gupta, Benjamin L. Maughan

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B117; DOI: 10.1158/1535-7163.TARG-17-B117

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological

Pages

Articles

Info for

About MCT